PharmaCyte Biotech (PMCB) Total Current Liabilities (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Total Current Liabilities of $826424.0 for Q2 2026, down 71.64% year-over-year from $2.9 million in Q2 2025, and down 50.76% quarter-over-quarter from $1.7 million in Q1 2026.
PharmaCyte Biotech (PMCB) Total Current Liabilities (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Total Current Liabilities for 16 consecutive years, with $826424.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities fell 71.64% year-over-year to $826424.0; the TTM figure through Apr 2026 stood at $826424.0 (down 71.64% YoY), while the FY2026 annual figure was $826424.0, down 71.64% from the prior year.
- Total Current Liabilities slipped to $826424.0 in Q2 2026 per PMCB's latest filing, from $1.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $7.5 million in Q1 2024 and bottomed at $586581.0 in Q2 2023.
- Historically, Total Current Liabilities has averaged $2.7 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 1165.17% — and 2025, when it plunged 85.8%.
- PharmaCyte Biotech's Total Current Liabilities stood at $1.3 million in 2022, then surged by 299.62% to $5.2 million in 2023, then dropped by 8.84% to $4.8 million in 2024, then sank by 66.97% to $1.6 million in 2025, then plunged by 47.61% to $826424.0 in 2026.
- Business Quant data shows PMCB's Total Current Liabilities at $826424.0 in Q2 2026, $1.7 million in Q1 2026, and $1.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 630.93 Mn |
| 10 | PharmaCyte Biotech | 4.36 Mn | 4.36 Mn | - | 826,424.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 826,424.00 |
| Jan 31, 2026 | 1.68 Mn |
| Oct 31, 2025 | 1.58 Mn |
| Jul 31, 2025 | 1.06 Mn |
| Apr 30, 2025 | 2.91 Mn |
| Jan 31, 2025 | 1.19 Mn |
| Oct 31, 2024 | 4.78 Mn |
| Jul 31, 2024 | 7.47 Mn |
| Apr 30, 2024 | 7.42 Mn |
| Jan 31, 2024 | 7.54 Mn |
| Oct 31, 2023 | 5.24 Mn |
| Jul 31, 2023 | 1.52 Mn |
| Apr 30, 2023 | 586,581.00 |
| Jan 31, 2023 | 827,834.00 |
| Oct 31, 2022 | 1.31 Mn |
| Jul 31, 2022 | 1.09 Mn |
| Apr 30, 2022 | 704,370.00 |
| Jan 31, 2022 | 612,976.00 |
| Oct 31, 2021 | 186,122.00 |
| Jul 31, 2021 | 924,974.00 |